Literature DB >> 11988408

The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results.

Polly A Marchbanks1, Jill A Mcdonald, Hoyt G Wilson, Nancy M Burnett, Janet R Daling, Leslie Bernstein, Kathleen E Malone, Brian L Strom, Sandra A Norman, Linda K Weiss, Jonathan M Liff, Phyllis A Wingo, Ronald T Burkman, Suzanne G Folger, Jesse A Berlin, Dennis M Deapen, Giske Ursin, Ralph J Coates, Michael S Simon, Michael F Press, Robert Spirtas.   

Abstract

PURPOSE: This paper presents methods and operational results of a population-based case-control study examining the effects of oral contraceptive use on breast cancer risk among white and black women aged 35-64 years in five U.S. locations.
METHODS: Cases were women newly diagnosed with breast cancer during July 1994 through April 1998. Controls were identified through random digit dialing (RDD) using unclustered sampling with automated elimination of nonworking numbers. Sampling was density-based, with oversampling of black women. In-person interviews were conducted from August 1994 through December 1998. Blood samples were obtained from subsets of cases and controls, and tissue samples were obtained from subsets of cases. A computerized system tracked subjects through study activities. Special attention was devoted to minimizing exposure misclassification, because any exposure-disease associations were expected to be small.
RESULTS: An estimated 82% of households were screened successfully through RDD. Interviews were completed for 4575 cases (2953 whites; 1622 blacks) and 4682 controls (3021 whites; 1661 blacks). Interview response rates for cases and controls were 76.5% and 78.6%, respectively, with lower rates for black women and older women.
CONCLUSIONS: The methodologic details of this large collaboration may assist researchers conducting similar investigations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988408     DOI: 10.1016/s1047-2797(01)00274-5

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  54 in total

1.  Examination of ancestral informative markers and self-reported race with tumor characteristics of breast cancer among Black and White women.

Authors:  Kerryn W Reding; Christopher S Carlson; Orsalem Kahsai; Christina C Chen; Andrew McDavid; David R Doody; Chu Chen; India Ornelas; Kimberly Lowe; Leslie Bernstein; Linda Weiss; Jill A McDonald; Michael S Simon; Brian Strom; Polly A Marchbanks; Ronald Burkman; Robert Spirtas; Jonathan M Liff; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2012-05-31       Impact factor: 4.872

2.  A case-control study of body mass index and breast cancer risk in white and African-American women.

Authors:  Paula Berstad; Ralph J Coates; Leslie Bernstein; Suzanne G Folger; Kathleen E Malone; Polly A Marchbanks; Linda K Weiss; Jonathan M Liff; Jill A McDonald; Brian L Strom; Michael S Simon; Dennis Deapen; Michael F Press; Ronald T Burkman; Robert Spirtas; Giske Ursin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

3.  Oral contraceptive formulation and risk of breast cancer.

Authors:  Polly A Marchbanks; Kathryn M Curtis; Michele G Mandel; Hoyt G Wilson; Gary Jeng; Suzanne G Folger; Jill A McDonald; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Phyllis A Wingo; Michael S Simon; Sandra A Norman; Brian L Strom; Giske Ursin; Linda K Weiss; Ronald T Burkman; Robert Spirtas
Journal:  Contraception       Date:  2011-09-28       Impact factor: 3.375

4.  Hormone therapy and fatal breast cancer.

Authors:  Sandra A Norman; Anita L Weber; A Russell Localio; Polly A Marchbanks; Giske Ursin; Brian L Strom; Linda K Weiss; Ronald T Burkman; Leslie Bernstein; Dennis M Deapen; Suzanne G Folger; Michael S Simon; Marion R Nadel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-05       Impact factor: 2.890

5.  Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer.

Authors:  Kerryn W Reding; David R Doody; Anne McTiernan; Li Hsu; Scott Davis; Janet R Daling; Peggy L Porter; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2010-09-29       Impact factor: 4.872

6.  Polymorphisms in nucleotide excision repair genes and endometrial cancer risk.

Authors:  Jennifer A Doherty; Noel S Weiss; Sherianne Fish; Wenhong Fan; Melissa M Loomis; Lori C Sakoda; Mary Anne Rossing; Lue Ping Zhao; Chu Chen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

7.  Timing of menarche and first full-term birth in relation to breast cancer risk.

Authors:  Christopher I Li; Kathleen E Malone; Janet R Daling; John D Potter; Leslie Bernstein; Polly A Marchbanks; Brian L Strom; Michael S Simon; Michael F Press; Giske Ursin; Ronald T Burkman; Suzanne G Folger; Sandra Norman; Jill A McDonald; Robert Spirtas
Journal:  Am J Epidemiol       Date:  2007-10-26       Impact factor: 4.897

8.  Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women.

Authors:  Veronica Wendy Setiawan; Li-Hao Chu; Esther M John; Yuan Chun Ding; Sue A Ingles; Leslie Bernstein; Michael F Press; Giske Ursin; Christopher A Haiman; Susan L Neuhausen
Journal:  Cancer Genet Cytogenet       Date:  2008-02

9.  Associations between the CYP17, CYPIB1, COMT and SHBG polymorphisms and serum sex hormones in post-menopausal breast cancer survivors.

Authors:  Page E Abrahamson; Shelley S Tworoger; Erin J Aiello; Leslie Bernstein; Cornelia M Ulrich; Frank D Gilliland; Frank Z Stanczyk; Richard Baumgartner; Kathy Baumgartner; Bess Sorensen; Rachel Ballard-Barbash; Anne McTiernan
Journal:  Breast Cancer Res Treat       Date:  2006-11-01       Impact factor: 4.872

10.  Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior.

Authors:  Laura P Forsythe; Catherine M Alfano; Stephanie M George; Anne McTiernan; Kathy B Baumgartner; Leslie Bernstein; Rachel Ballard-Barbash
Journal:  Breast Cancer Res Treat       Date:  2012-12-15       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.